Enjoy complimentary customisation on priority with our Enterprise License!
The human papillomavirus (HPV) therapeutics market size is estimated to grow by USD 953.3 million at a CAGR of 5.15% between 2022 and 2027. The growth of the market depends on several factors, including the advent of vaccines, the development of oral vaccines for HPV, and strong disease progression.
It also includes an in-depth analysis of drivers, trends, and challenges. Furthermore, the report includes historic market data from 2017 to 2021.
To learn more about this report, Download Report Sample
The advent of vaccines is notably driving the market growth, although factors such as the lack of curative therapies may impede the market growth. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
The advent of vaccines is notably driving the market growth. According to the CDC, approximately one-fourth of the population in the US has HPV, and it is the most common sexually transmitted infection. Vaccines have strong efficacy in the prevention of various disease-causing viruses. They are highly effective in the prevention of various indications.
There are three approved vaccines for HPV, namely GARDASIL, GARDASIL 9, and CERVARIX, all of which are approved to prevent and treat HPV type 16 and type 18. Vendors are researching vaccines for the prevention and treatment of HPV. For instance, MedImmune, a subsidiary of AstraZeneca, is conducting research on the development of MEDI0457, a vaccine that is being studied to prevent cervical cancer and head and neck cancer caused by HPV type 16 and type 18. Hence, the increasing research and advances in vaccines are expected to drive the growth of the global market during the forecast period.
The R&D of new drugs for Orthostatic Hypotension (OH) treatment is a key trend influencing the market growth. OH refers to an abnormal drop in blood pressure and is linked to a high risk of fatalities, syncope, falls, and cognitive decline. Certain cardiovascular and psychotropic drugs lead to drug-related OH. Other risk factors include comorbidities, advanced age, neurogenic autonomic dysfunction, and others.
Individuals with postural orthostatic tachycardia syndrome (POTS) face orthostatic hypotension. Their heart rate rises upon standing, along with symptoms such as dizziness, syncope, weakness, migraines, chronic aches and pains, gastrointestinal issues, and exhaustion. There is a high unmet need for drugs in the OH drugs market due to a lack of approval with substantial clinical efficiency and a high safety profile. Hence, the increasing focus on the R&D of novel drugs will create a positive impact on the use of HPV vaccines.
The lack of curative therapies may impede the market growth. This is a highly prevalent virus. According to the CDC, in the US, the prevalence of this was about 25% in 2018. The approved vaccines decrease the risk of but do not completely ensure its prevention.
The global market does not have any curative methods for indications caused. Curative therapies are still in the early stages of development by various research institutions and vendors. As a result, the mortality rate due to this is increasing. Therefore, the preference for alternative treatment options such as radiation therapy and cryotherapy is increasing.
The market research report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.
Global Human Papillomavirus Therapeutics Market Customer Landscape
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
2A Pharma ApS - The company offers L2 based HPV vaccine. It also offers vaccines and therapeutics based on the AAVLP platform.
The market report also includes detailed analyses of the competitive landscape of the market and information about 15 market companies, including:
Qualitative and quantitative analysis of vendors has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize vendors as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize vendors as dominant, leading, strong, tentative, and weak.
The market share growth by the parenteral segment will be significant during the forecast period. The market is dominated by vaccines administered through the parenteral route, such as under the skin, in a muscle, in a vein, and around the spinal cord. This route helps the vaccines in reaching the HPV-affected area without losing efficacy.
Get a glance at the market contribution of various segments Request a PDF Sample
The parenteral segment was valued at USD 2,557.11 million in 2017 and continued to grow until 2021. The increasing awareness about these and the strong efficacy of vaccines toward preventing this from progressing into cancer or other indications are expected to positively impact this segment during the forecast period. As a result, numerous people are undergoing vaccination, which is increasing the share of the segment. Therefore, the parenteral segment of the global market is expected to grow during the forecast period.
For more insights on the market share of various regions Request PDF Sample now!
North America is estimated to account for 50% of the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.
The high sales of approved therapeutics and vaccines and the strong prevalence of various types of HPV are driving the growth of the market in North America. According to the CDC, this is the most common sexually transmitted virus in the US. They can also lead to various types of indications such as cancer, genital warts, and multiple other infections. Therefore, there is a need to develop advanced prevention and treatment options. The pipeline in the region has multiple vaccines, which are expected to be launched during the second half of the forecast period. Advances in research on pipeline molecules are expected to contribute to market growth.
The report forecasts market growth by revenue at global, regional, and country levels and provides an analysis of the market growth and trends opportunities from 2017 to 2027.
The market focuses on screening, diagnosis, and treatment for non-emergency diseases associated with HPV. However, there is a supply shortage of HPV tests and vaccines, despite government initiatives and funding to improve HPV vaccination coverage.
The market addresses the prevalence of HPV-related diseases, particularly in the cervical cancer segment, where organizations like the American Cancer Society (ACS) and Japan Human Papillomavirus play significant roles in screening and awareness initiatives. Research and development efforts aim to enhance healthcare infrastructure and strategic initiatives for companies like Wantai BioPharm and Roche Diagnostics, known for their HPV-related products. Stringent regulations govern the market, ensuring the quality and safety of HPV therapeutics. Collaborations with organizations such as the Cancer Awareness Prevention and Early Detection Trust (CAPED) further advance screening and immunization programs, including the use of the Gardasil 9 human papillomavirus vaccine in national immunization programs.
Human Papillomavirus (HPV) Therapeutics Market Scope |
|
Report Coverage |
Details |
Page number |
161 |
Base year |
2022 |
Historic period |
2017-2021 |
Forecast period |
2023-2027 |
Growth momentum & CAGR |
Accelerate at a CAGR of 5.15% |
Market growth 2023-2027 |
USD 953.3 million |
Market structure |
Concentrated |
YoY growth 2022-2023(%) |
4.24 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 50% |
Key countries |
US, Canada, Brazil, Germany, and China |
Competitive landscape |
Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks |
Key companies profiled |
2A Pharma ApS, AbbVie Inc., Bavarian Nordic AS, BioVaxys Technology Corp., F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, ISA Pharmaceuticals BV, Serum Institute of India Pvt. Ltd., Walvax Biotechnology Co. Ltd., Xiamen Innovax Biotech Co. Ltd., Merck and Co. Inc., Bausch Health Co. Inc., and Inovio Pharmaceuticals Inc. |
Market dynamics |
Parent market analysis, Market Forecasting, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the forecast period |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Route of Administration
7 Market Segmentation by Indication
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.